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Stephen R. Daniels, MD, PHD
Aurora, ColoradoAfter decades of research, there is no question that
atherosclerosis begins early in life and is progressive, ul-
timately leading to the cardiovascular outcomes of coro-
nary heart disease and cerebrovascular disease in adult life
(1). It is also clear that there are important risk factors
that, when present, increase the risk of adverse outcomes
(2). These risk factors include elevated low-density lipo-
protein cholesterol (LDL-C), low high-density lipopro-
tein cholesterol, hypertension, diabetes mellitus, cigarette
smoking, and obesity. The recently published American
College of Cardiology (ACC)/American Heart Associa-
tion (AHA) guidelines on prevention of atherosclerotic
cardiovascular disease (ASCVD) in adults emphasizes
understanding the level of risk based on risk factors and,
when appropriate, implementing evidence-based life-
style and pharmacological treatment to prevent adverse
cardiovascular outcomes (3,4). An important advance in
these new guidelines is that they are based not on evidence
related to reduction of intermediate outcomes, such as
levels of risk factors, but on evidence related to the pre-
vention of important health outcomes, such as coronary
events and stroke (5).See page 2779Although this is an important advance for the prevention
of ASCVD in adults, it leaves open the question of pre-
vention of adverse cardiovascular outcomes starting in
childhood and adolescence. The ACC/AHA Guideline on
the Assessment of Cardiovascular Risk makes it clear that,
although the concept of lifetime risk is important, at present,
the existing data only support an approach to estimating
10-year risk of ASCVD (3). They concluded that long-
term and lifetime risk information may be used most
appropriately to motivate therapeutic lifestyle modiﬁcation
in younger individuals at lower 10-year risk, but evidence isFrom the Department of Pediatrics, University of Colorado School of Medicine,
Children’s Hospital Colorado, Aurora, Colorado. Dr. Daniels has reported that he has
no relationships relevant to the contents of this paper to disclose.
Manuscript received January 6, 2014; accepted January 16, 2014.lacking for long-term and lifetime risk assessment to be used
in guiding decisions regarding pharmacological therapy in
the prevention of ASCVD.
The concept of lifetime risk remains important,
however. Evidence from observational studies demon-
strates that individuals who maintain a low-risk proﬁle,
including normal blood pressure, normal body mass in-
dex, normal total cholesterol, no diabetes, and no ciga-
rette smoking through childhood, adolescence, and young
adulthood up to 50 years of age have an exceedingly low
risk of subsequent ASCVD and a substantially longer life
expectancy (6). Additional data from these observational
studies demonstrate that although genetics plays some
role in the ability to maintain low-risk status, much of
this favorable status is achieved by maintaining an optimal
cardiovascular lifestyle or health factors throughout early
life (7).
With this background, in this issue of the Journal, Rob-
inson and Gidding (8) present an argument for a very early
and very aggressive approach, including aggressive pharma-
cological intervention to “cure” atherosclerosis and therefore
prevent ASCVD. They propose a very early moderate-
intensity statin LDL-C–lowering strategy in children and
adolescents and an early, very aggressive LDL-C–lowering
strategy in young adults, including the use of statins and
possibly other lipid-lowering agents. In support of this
strategy, they present several lines of evidence. Some of the
evidence comes from observational studies of children and
adolescents, some from the limited clinical trials in children
and adolescents, and additional evidence from clinical
trials of adults. Important evidence from adult clinical trials
includes the legacy effect of intervention with statins that
favor the intervention over the placebo group as long as
10 years after the trial has been completed. Presumably,
both groups are treated with the intervention (statins)
thereafter, but the intervention group continues to have a
lower rate of events (9).
Although the approach suggested by Robinson and
Gidding (8) has some evidence to support it, and it may
present hypotheses to be tested in future trials, it also has
substantial gaps in the supportive evidence and problems
with any real-life strategy to implement their approach. The
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2787ﬁrst concern is theoretical. They present the approach as a
“vaccination” and “cure.” It is not clear that the analogy to
vaccinations is useful in the context of atherosclerosis.
Vaccination to prevent infectious disease has a strong bio-
logical underpinning related to the creation of a pre-emptive
biological immune response, which can then prevent infec-
tion when there is future exposure to the infectious agent.
This does not appear to be operative in the prevention of
atherosclerosis and ASCVD. It is also unclear that athero-
sclerosis can be “cured.”
Another important concern behind this entire discussion
is that we currently have no methods to image and evaluate
the presence and progression of the atherosclerotic process,
particularly the early stages of this process. This is 1 reason
why, historically, we have been forced to focus on risk fac-
tors, which can be measured and followed. However, as
Psaty and Weiss (5) have noted, management of risk factors
does not always relate directly to prevention of ASCVD.
Robinson and Gidding (8) propose that carotid intima-
media thickness (CIMT) is the best noninvasive measure
for assessing atherosclerosis. However, the ACC/AHA risk
assessment guidelines speciﬁcally indicate that CIMT is
not recommended for routine measurement for clinical
practice for adults (3). Even if CIMT were to be recom-
mended, it should be remembered that it is a surrogate
measure, not a direct measure, of atherosclerosis in the
coronary or cerebral arteries.
Another concern is that Robinson and Gidding (8) are
not very speciﬁc about how their proposed approach would
be implemented in practice. They mention patients with
heterozygous familial hypercholesterolemia, which is a group
at high lifetime risk of ASCVD (10). They also mention
young patients with type 2 diabetes mellitus, which is
another group that appears to be at high lifetime ASCVD
risk (11). However, they also mention young patients with
obesity, insulin resistance, pre-hypertension, elevated tri-
glycerides, and low high-density lipoprotein cholesterol. The
lifetime risk of ASCVD is much less clear in these patients,
and the balance between potential beneﬁts and risks of very
aggressive intervention may be substantially less favorable. It
is also not clear at which age they would propose to initiate
the aggressive intervention and if the intervention is to be
intermittent rather than continuous, how long the inter-
vention would last, and how one would determine whether it
was effective.
So, where does this leave us in practical terms? It is clear
that a deeper evidence base regarding the initiation of
atherosclerosis in childhood and the role of risk factors and
their progression over time is needed. Better measures of
atherosclerosis via imaging would provide a tremendous
advance. Some of the needed evidence will come from
observational studies, but better clinical trials of the safety
and efﬁcacy of lifestyle and pharmacological intervention
with appropriate duration and outcomes will also be needed.
Studies will need to span the age ranges from risk factor
development in childhood to important health outcomes inadulthood. However, it must be recognized that such long-
term studies are very difﬁcult to perform and do not provide
meaningful answers for decades. In the meantime, we need
to develop useful approaches to calculating long-term risk
of ASCVD in young people.
Although the evidence base continues to develop, the
Integrated Guidelines for Cardiovascular Health and Risk
Reduction in Children and Adolescents continue to pro-
vide the best evidence-based approach to the evaluation
and management of risk for ASCVD in young individuals
(12). These guidelines focus on understanding the health
impact of the entire constellation of cardiovascular disease
risk factors. They focus on primordial prevention of risk
factors through adoption of lifelong healthy behaviors. For
those children and adolescents in whom risk factors
emerge, the focus is on more intensive lifestyle interven-
tion to promote a healthful diet and levels of physical ac-
tivity. Consideration of more aggressive pharmacological
intervention is reserved for a very small proportion of
children who are deemed to be at very high risk, usually
because of genetic abnormalities, leading to quite high
levels of risk factors.
Robinson and Gidding (8) should be commended for a
piece that provokes thought and provides hypotheses to be
tested in future research. However, current clinical practice
should be grounded in the best current evidence regarding
efﬁcacy and safety (12).
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